TY-52156|cas:934369-14-9|西域试剂

TY-52156,99.62%

产品编号：Bellancom-19736| CAS NO：934369-14-9| 分子式：C₁₈H₁₉Cl₂N₃O| 分子量：364.27

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19736	￥700.00	杭州北京（现货）
Bellancom-19736	￥1100.00	杭州北京（现货）
Bellancom-19736	￥3800.00	杭州北京（现货）
Bellancom-19736	￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TY-52156

产品介绍

TY-52156 是一种有效、选择性的 S1P₃ 受体拮抗剂，K_i 值为 110 nM。

生物活性

TY-52156 is a potent and selective S1P₃ receptor antagonist with a K_i value of 110 nM.

体外研究

TY-52156 inhibits the S1P₃ receptor-dependent increase in [Ca²⁺]_i.
TY-52156 shows submicromolar potency and a high degree of selectivity for S1P₃ receptor.
TY-52156 (10 μM; 10 min) inhibits S1P-induced p44/p42 MAPK phosphorylation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Chinese hamster ovary K1 cells
Concentration:	10 μM
Incubation Time:	10 min
Result:	Inhibited S1P-induced p44/p42 MAPK phosphorylation.

体内研究
(In Vivo)

TY-52156 (10 mg/kg, 30 mg/kg; p.o.) suppresses S1P₃ receptor-induced bradycardia after oral administration in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SD rats (290–340 g)
Dosage:	10 mg/kg, 30 mg/kg
Administration:	Oral administration
Result:	Inhibited S1P₃ receptor-induced bradycardia after oral administration in vivo.

体内研究

TY-52156 (10 mg/kg, 30 mg/kg; p.o.) suppresses S1P₃ receptor-induced bradycardia after oral administration in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SD rats (290–340 g)
Dosage:	10 mg/kg, 30 mg/kg
Administration:	Oral administration
Result:	Inhibited S1P₃ receptor-induced bradycardia after oral administration in vivo.

体内研究

TY-52156 (10 mg/kg, 30 mg/kg; p.o.) suppresses S1P₃ receptor-induced bradycardia after oral administration in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SD rats (290–340 g)
Dosage:	10 mg/kg, 30 mg/kg
Administration:	Oral administration
Result:	Inhibited S1P₃ receptor-induced bradycardia after oral administration in vivo.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (274.52 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7452 mL	13.7261 mL	27.4522 mL
5 mM	0.5490 mL	2.7452 mL	5.4904 mL
10 mM	0.2745 mL	1.3726 mL	2.7452 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.86 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液